Jazz Pharmaceuticals Buys Actio Biosciences For $820 Million, Extending Its Rare Epilepsy Push

Jazz Pharmaceuticals said Monday it will acquire Actio Biosciences for $820 million in cash, with Actio also eligible for up to $500 million in additional milestone payments. The companies expect the deal to close by the end of this year.

The main asset is ABS-1230, a once-daily oral small molecule designed to treat KCNT1-related epilepsy, a genetic form of epilepsy that affects about 2,500 patients in the U.S., according to the companies. Both sources describe a disease with no FDA-approved therapies and limited benefit from existing anti-seizure drugs, creating the kind of concentrated unmet need that fits Jazz’s rare neurology strategy.

The Data

ABS-1230 is a KCNT1 ion channel inhibitor. In KCNT1-related epilepsy, mutations in the KCNT1 gene lead to overactive potassium channels that allow electric charges to flow across cell membranes in a way that can trigger seizures.

Actio has advanced ABS-1230 into the Phase 2 portion of an ongoing Phase 1b/2a study. MedCity News identified that trial as a Phase 1b/2a program that could serve as the registrational study supporting a submission seeking FDA approval, while BioSpace said the ongoing Phase 1b/2a KYRON trial is designed to serve as the registrational study. BioSpace also reported that the drug has received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations and is part of the FDA’s Rare Disease Evidence Principles program for ultra-rare disease therapies.

The public evidence base remains limited. MedCity News reported that Actio has not publicly disclosed data for ABS-1230. BioSpace, citing the companies’ release, said an early proof-of-concept trial tied the candidate to meaningful seizure reductions in children with KCNT1 epilepsy. Jazz President and CEO Renee Gala described the emerging clinical profile as “highly encouraging” in a prepared statement, but the current information available publicly is still relatively sparse for an asset carrying a headline value of up to $1.32 billion.

That makes the registrational framing important. For Jazz, this is not simply a platform acquisition or an early discovery bet; it is a purchase of a clinical-stage asset positioned around a rare disease development path that could potentially move on an accelerated timeline if trial results continue to support the mechanism.

The Commercial Picture

Jazz’s rationale is tied to an epilepsy business it has assembled through transactions. Its leading neuroscience product is Epidiolex, the cannabidiol-derived epilepsy drug acquired in the 2021 purchase of GW Pharmaceuticals. MedCity News said Epidiolex crossed the $1 billion revenue threshold last year. BioSpace added a more recent operating datapoint, citing Truist Securities analysts who wrote last week that Epidiolex “remains the epilepsy anchor at +16% YoY,” with $292 million in second-quarter revenue this year.

Against that backdrop, ABS-1230 broadens Jazz’s reach from established rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome into a genetically defined condition with no approved therapies. The strategic appeal is less about patient numbers alone than about precision positioning: a targeted therapy in an ultra-rare epilepsy can strengthen a specialist commercial franchise if the clinical effect is clear enough to support adoption.

Competition is already forming, though from multiple modalities. MedCity News reported that Servier has reached Phase 1b/2 testing with an antisense oligonucleotide for KCNT1-related epilepsy. UCB has a preclinical small molecule from a collaboration with Praxis Precision Medicines, and Atalanta Therapeutics has a preclinical small-interfering RNA program designed to reduce the relevant target. That mix means Jazz is buying into a race that remains early but is no longer uncontested.

The Road Here

Jazz has been adding to its neuroscience pipeline beyond Epidiolex. MedCity News noted that the company licensed JZP053, formerly SAN2355, from Saniona nearly a year ago for $42 million up front. That small molecule activator of two ion channels is in preclinical development.

Actio, for its part, launched a few years ago and raised $55 million in Series A financing in 2023, according to BioSpace. After the acquisition closes, Actio will spin out into a privately held independent company containing its remaining assets, and Jazz will keep a minority stake in that spinout. BioSpace said the new company will focus on ABS-0871, a small molecule TRPV4 inhibitor for Charcot-Marie-Tooth disease type 2C.

The signal in this deal is that Jazz is continuing to build rare epilepsy through bolt-on transactions centered on mechanistically differentiated assets rather than broad CNS scale. If ABS-1230 can translate early signal into registrational evidence, the company gains a potential first-in-class product that deepens a franchise it already knows how to commercialize.